SCHEMBL823700

SCHEMBL823700

CC(=O)Oc1ccc(F)cc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.50
CYP4A11 Q02928 1/20 0.50
TSHR P16473 5/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 2/20 0.47
RAB9A P51151 2/20 0.47
GAA P10253 1/20 0.47
CFD P00746 2/20 0.46
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
FAAH O00519 2/20 0.45
HPGD P15428 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
ESR1 P03372 1/20 0.44
ITGB3 P05106 1/20 0.44
ITGA2B P08514 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17204990 0.98 CYP4F2 (0.49) CYP4F2CYP4A11TSHRKDM4EALDH1A1
SCHEMBL5755257 0.86 TSHR (0.58) CYP4F2CYP4A11TSHRKDM4EALDH1A1
SCHEMBL9223703 0.85 CFD (0.53) CYP4F2CYP4A11TSHRKDM4EALDH1A1
SCHEMBL1991907 0.84 CYP4F2 (0.64) CYP4F2CYP4A11TSHRKDM4EALDH1A1
SCHEMBL10658758 0.83 CES2 (0.48) TSHRKDM4ERAB9ACES2CES1
SCHEMBL2914318 0.83 CES2 (0.48) TSHRKDM4ERAB9ACES2CES1
SCHEMBL18697359 0.83 CES2 (0.48) TSHRKDM4ERAB9ACES2CES1
SCHEMBL29462972 0.83 CES2 (0.48) TSHRKDM4ERAB9ACES2CES1
SCHEMBL18309868 0.83 MAPT (0.48) TSHRKDM4ERAB9ACES2CES1
SCHEMBL2615139 0.82 ACHE (0.46) CYP4F2CYP4A11TSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3848464-A1 METHOD FOR SITE-SPECIFIC MUTAGENESIS OF MEDICAGO SATIVA GENE BY USING CRISPR/CAS9 SYSTEM Guangdong Sanjie Forage Biotechnology Co., Ltd (CN) 2021-07-14 EP claimed
US-10483466-B2 P-doping cross-linking of organic hole transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2019-11-19 US claimed
EP-3114715-B1 P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS SIEMENS AG (DE) 2019-10-30 EP claimed
CN-109535080-A A kind of synthetic method of benzimidizole derivatives 广东省石油与精细化工研究院 2019-03-29 CN claimed
CN-108752218-A A kind of variation route prepared by Du Lutewei key intermediates 2,4- difluorobenzylamines 浙江沙星科技有限公司 2018-11-06 CN claimed
US-20180198069-A1 P-Doping Cross-Linking Of Organic Hole Transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2018-07-12 US claimed
CN-108059205-A For the up-flow adsorptive reactor of orthophosphates in Adsorption waste water 北京益清源环保科技有限公司 2018-05-22 CN claimed
CN-105601502-A Method for preparing acyl chloride by catalyzing phosgene and acid TIANJIN JINGYE FINE CHEMICALS CO LTD 2016-05-25 CN claimed
CN-105585478-A Preparation method of acyl chloride TIANJIN JINGYE FINE CHEMICALS CO LTD 2016-05-18 CN claimed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US claimed
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 US disclosed
CN-115054600-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2024-06-14 CN disclosed
WO-2023125825-A1 ANTICORONVIRAL COMPOUNDS AND COMPOSITIONS AND USES THEREOF SHANGHAI CUREGENE PHARMACEUTICAL CO., LTD. (CN) 2023-07-06 WO disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 US disclosed
US-6191164-B1 POTASSIUM CHANNEL MODULATORS; ANTIULCER AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 2001-02-20 US disclosed
US-6149977-A CONTACTING THE OXIDATIVE POLYMER WITH A CATALYTIC AMOUNT OF AN OXIDIZING ENZYME, SUCH AS HORSERADISH PEROXIDASE. ROHM AND HAAS COMPANY (US) 2000-11-21 US disclosed
EP-0950669-A2 Method of catalytic crosslinking of polymers and two-pack composition used therein ROHM AND HAAS COMPANY (US) 1999-10-20 EP disclosed
US-5891906-A Polyacetate-derived phorboids having anti-inflammatory and other uses PROCYON PHARMACEUTICALS, INC. (US) 1999-04-06 US disclosed
US-5886019-A REPLACEMENT OF HYDROXYMETHYL OR-ETHYL GROUP ON TRICYCLIC AROMATIC HETEROCYCLIC COMPOUNDS HAVING INDOLE, INDENE, BENZOFURAN OR BENZOTHIOPHENE SKELETON; ANTIINFLAMMATORY, ANTIVIRAL PROCYON PHARMACEUTICALS, INC. (US) 1999-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162863-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS CYP4F2 1460/4885CYP4A11 122/4885TSHR 3650/4885
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS CYP4F2 1460/4885CYP4A11 122/4885TSHR 3650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.